Brazil antitrust regulator known as Cade issued a final decision approving the merger between Hapvida and Intermedica without remedies, both companies said in filings.
- Closing of the transaction is expected to take place early in February
- Intermedica
said it will work with Hapvida to set up a schedule for steps to be completed until the closing of the deal - NOTE:
Brazil Regulator Backs Hapvida-Notre Dame Deal Without Remedies
To see the source of this information click
Original Story:
To contact the translator on this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.